Lexicon Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/16/2026)
| Balance Sheet | Total Assets | 184,987,000.00 | ROE | 58.13 % |
| Balance Sheet | Total Equity | 107,538,000.00 | ROA | -27.21 % |
| Cashflow | Capital Expenditures | -3,000,000.00 | P/FCF | -8.20 |
| Cashflow | Free Cash Flow | -70,851,000.00 | – | – |
| Cashflow | Operating Cash Flow | -67,851,000.00 | P/CF | -8.56 |
| Income | Earnings per Share (diluted) | -0.14 | Div. Yield | – |
| Income | Net Income | -50,341,000.00 | P/E | -11.43 |
| Income | Shares Outstanding | 363,053,000.00 | P/B | 5.40 |
| Income | Total Revenue | 49,803,000.00 | P/S | 11.66 |
Ratios calculated on: 10/14/2026
Company Description
Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. It has five drug programs in various stages of clinical development and has advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research. Its drug program includes LX4211, LX1032, LX1033, LX2931 and LX7101.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.lexgen.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more